Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008.
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study.
[Immunomodulation and neuroprotection in optic neuritis].
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
Episode 28 with Dr. Brenda Banwell on pediatric MS
Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
Extended interval dosing of natalizumab in multiple sclerosis.
Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions.
Individual Neuronal Subtypes Exhibit Diversity in CNS Myelination Mediated by Synaptic Vesicle Release.
Bilateral optic neuritis in a patient with Behçet's disease who respond to therapeutic plasma exchange.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination.
Effect of vitamin D on MS activity by disease-modifying therapy class.
Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.
Clarity Extension Study
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Epigenetics of Multiple Sclerosis: An Updated Review.
Fatigue and Comorbidities in Multiple Sclerosis.
Brain and BrainPET 2015
Prevalence of Multiple Sclerosis in the Republic of Moldova.

Pages